Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S6W-07401 · Session 6

Whether it will include the reported impact of diethylstilbestrol, also known as DES, stilbestrol and stilboestrol, on women and their chil…

Answered Asked by Monica Lennon Lab Lodged 13 Mar 2022

The question

To ask the Scottish Government whether it will include the reported impact of diethylstilbestrol, also known as DES, stilbestrol and stilboestrol, on women and their children in its ongoing assessment of historic forced adoption and requests for a formal apology and specialist support.

The answer

Answered by Clare Haughey on 30 Mar 2022 · 17 days after it was lodged, on time

The Scottish Government will consider all of the information received from people affected by historical adoption practices through our ongoing engagement activity before next steps are decided.
Regulation for the licensing, safety and efficacy of medicines is reserved to the UK Government and is the responsibility of the UK’s independent medicines regulator the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA, an executive agency of the Department of Health and Care (DHSC), is responsible for investigating any current safety concerns regarding licensing of diethylstilbestrol.

In the Official Report

No contribution in the Official Report cites S6W-07401 by reference.